RE:RE:RE:RE:RE:RussiaWhat I've had in mind for the North American and European country, is not to see PLI give all the rights for the PPPS, but rather seeing licencing for specific proteins for specific applications. There's a huge portofolio of proteins, that can be use in therapeutic. PLI won't be able to develop all of them. So the big boys can come in the game and pay for them. Shire paid for Viropharma, it was to access CINRYZE, for a rare disease in a 2 billions market. This is made with a plasma proteins, a C1 esterase inhibitor. So this kind of application have a high value. Won't you think if PLI can come up with similar proteins with a better purity and yield, there's possibilities here. So before seeing PLI signed them with foreign companies and lost market shares to them, they will probably consider doing it before.